Professor Winette Van der Graaf

Professor of Personalised Oncology at the ICR and Consultant in Medical Oncology at The Royal Marsden

Professor Winette van der Graaf leads the Clinical and Translational Sarcoma team at the ICR and specialises in developing new therapies to improve outcomes for sarcoma patients.

Originally from the Netherlands, Professor Van der Graaf led the pivotal Phase III trial of the targeted drug pazopanib for soft-tissue sarcoma, leading to its registration by the US Food and Drug Administration and the European Medicines Agency.

For her, personalised oncology is a combination of precision medicine and adapting treatment and care to the needs of patients of different ages. She is known for her innovations in the care of young people and elderly patients. In 2015, she co-founded the Radboud Elderly Cancer programme, before joining the ICR and The Royal Marsden later that year.

“My work is focused on sarcoma, a group of at least 70 different tumours of the bone and soft tissues that can affect people of any age, and may arise anywhere in the body,” she says. “Some predominantly affect adolescents and young adults, which makes treatment extremely challenging. We are investigating new treatment options to subsequently set up clinical studies.

70+

number of different sarcomas

"It is not logical to have care organised only by tumour type. The treatments and needs of the young and the elderly differ substantially"

Curriculum vitae

1986 Graduates in medicine from the University of Groningen

1992 Joins department of Medical Oncology at University Medical Centre in Groningen

2010 Appointed Head of Medical Oncology at Radboud University

2012 Appointed Chair of the European Organisation for Research and Treatment of Cancer’s soft tissue and bone sarcoma group

2013 Appointed Chair of the Dutch adolescent and young adult cancer programme

2015 Joins the ICR and The Royal Marsden